Jim Simons’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Jim Simons’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-414,425	Closed	-$132K	–	3684
2018 Q1	$132K	Buy	+414,425	New	+$619K	﹤0.01%	3234
2016 Q1	–	Sell	-33,625	Closed	-$1.25M	–	3643
2015 Q4	$1.25M	Buy	33,625 +12,500	+59%	+$552K	﹤0.01%	2360
2015 Q3	$1.03M	Buy	+21,125	New	+$1.48M	﹤0.01%	2362
2015 Q2	–	Sell	-2,288	Closed	-$82K	–	3491
2015 Q1	$82K	Buy	+2,288	New	+$67.7K	﹤0.01%	3032
2014 Q4	–	Sell	-3,338	Closed	-$51K	–	3230
2014 Q3	$51K	Sell	3,338 -12,274	-79%	-$258K	﹤0.01%	2711
2014 Q2	$423K	Buy	15,612 +3,437	+28%	+$84.8K	﹤0.01%	2382
2014 Q1	$326K	Buy	12,175 +3,837	+46%	+$97.4K	﹤0.01%	2496
2013 Q4	$205K	Buy	8,338 +2,332	+39%	+$60.1K	﹤0.01%	2610
2013 Q3	$193K	Buy	6,006 +1,263	+27%	+$39.2K	﹤0.01%	2586
2013 Q2	$141K	Buy	+4,743	New	+$177K	﹤0.01%	2576

Other funds holding ANTH

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Jim Simons's ANTH Position: Q2 2018 in Review

Jim Simons sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 414,425 shares — an estimated $132K sold.

Jim Simons first reported a position in ANTH in Q2 2013 and held it in 10 quarters. The position peaked at $1.25M in Q4 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

Jim Simons reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Jim Simons sold 414,425 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $132K.
Jim Simons first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
Jim Simons's Anthera Pharmaceuticals, Inc. position peaked at $1.25M in Q4 2015.
5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on Renaissance Technologies's 13F filing for Q2 2018, filed 13 Aug 2018.